StockTitan

@stocktitan.net

4 days ago

20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera’s Oncology Platform Natera (NASDAQ: NTRA) will present 20 abstracts at AACR Annual Meeting April 17–22, 2026, spanning AI, ctDNA decision-making, MRD and real-world evidence.Key data: models trained on >45,000 colorectal cases; AI AUROC 0.98 (MSI) and 0.93 (BRAF V600E); breast ML precision 93.5%/recall 91.1%; ctDNA study of 465 MSI-H metastatic CRC patients showed ~40% early ctDNA clearance and 3-year OS of 96% for early Signatera-negative patients.

#NTRA 20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera’s Oncology Platform

www.stocktitan.net/news/NTRA/20-abstracts-a...

StockTitan

@stocktitan.net

1 week ago

Blood test helped some women over 70 with breast cancer avoid surgery In a 43-patient study, 68% tested MRD-negative before treatment and none progressed, suggesting Signatera could guide non-surgical care.

#NTRA SignateraTM MRD Identifies Breast Cancer Patients Who Can Forgo Surgery

www.stocktitan.net/news/NTRA/signatera-tm-m...

StockTitan

@stocktitan.net

4 weeks ago

New genome test from Natera and MyOme targets 5-year rare disease delays 5-year rare disease diagnosis delays persist; Zenith adds long-read methylation and a genome-first approach via Natera starting Q2 2026.

#NTRA MyOme Debuts Zenith™ Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026

www.stocktitan.net/news/NTRA/my-ome-debuts-...

StockTitan

@stocktitan.net

4 weeks ago

Natera Announces Commercial Launch of Zenith™ Genomics for Rare Disease Diagnosis Natera (NASDAQ: NTRA) announced the commercial launch of Zenith genomics, a next-generation whole genome sequencing assay for rare disease diagnosis, on March 12, 2026.Zenith uses a whole-genome backbone plus long-read sequencing confirmation to improve detection of hard-to-detect features like tandem repeat expansions. The launch follows an exclusive partnership with MyOme and leverages Natera's EMR integration, clinical support, and nationwide commercial footprint. The company cites 30 million Americans affected by rare disease, typical diagnostic journeys of 4–7 years, and a 2019 U.S. economic burden estimate of $997 billion to frame market need. Natera is presenting Zenith at the 2026 ACMG meeting to showcase platform performance and real-world utilization.

#NTRA Natera Announces Commercial Launch of Zenith™ Genomics for Rare Disease Diagnosis

www.stocktitan.net/news/NTRA/natera-announc...

StockTitan

@stocktitan.net

1 month ago

Signatera™ MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation Natera (NASDAQ: NTRA) will present 11 abstracts at ASCO GU (Feb 26-28, 2026) showing Signatera MRD's potential across genitourinary cancers.Key findings include 73–77% ctDNA clearance in MIBC, Signatera-negativity linked to high two-year bladder-intact EFS (88.6% and 91%), and complementary utDNA+ctDNA perioperative stratification.

#NTRA Signatera™ MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation

www.stocktitan.net/news/NTRA/signatera-tm-m...

StockTitan

@stocktitan.net

1 month ago

Genetic tester Natera tops $2.3B sales in 2025 yet still posts $208M loss 2025 cash inflow reached $107.6M as Natera grew test volumes and gross margin, and it now guides 2026 revenue to $2.62B–$2.70B with positive cash inflow.

#NTRA Natera Reports Fourth Quarter and Full Year 2025 Financial Results

www.stocktitan.net/news/NTRA/natera-reports...

StockTitan

@stocktitan.net

2 months ago

Prospera™ Featured in Landmark Interventional Study Advancing Lung Transplant Care Natera, Inc., a global leader in cell-free DNA and precision medicine, today announced the publication of a new prospective clinical trial in Transplantation Direct. The study, which was conducted by The Ohio State University Wexner Medical Center, was initiated to explore whether donor-derived cell-free DNA surveillance, and specifically...

#NTRA Prospera™ Featured in Landmark Interventional Study Advancing Lung Transplant Care

www.stocktitan.net/news/NTRA/prospera-tm-fe...

StockTitan

@stocktitan.net

2 months ago

Natera Publishes Clinical Validation of Latitude™ Tissue-Free MRD Test in Colorectal Cancer Natera (NASDAQ: NTRA) published a peer-reviewed validation of its Latitude tissue-free MRD (tfMRD) assay in colorectal cancer in npj Precision Oncology, analyzing 1,230 timepoints from 195 patients in the GALAXY trial.Key results: longitudinal sensitivity 84.4% with a median lead time of 4.6 months before radiographic recurrence; sample-level specificity 97.2% and patient-level specificity 92.1%; MRD-positivity strongly prognostic (HR 10 in MRD setting; HR 31.9 in surveillance; p<0.001). In high-risk stage II/III patients, MRD-positive status predicted substantial adjuvant chemotherapy benefit (adj.HR=0.014, P<0.0001). The study supports a MolDX submission to CMS and notes Latitude complements tumor-informed Signatera when tissue is unavailable.

#NTRA Natera Publishes Clinical Validation of Latitude™ Tissue-Free MRD Test in Colorectal Cancer

www.stocktitan.net/news/NTRA/natera-publish...

StockTitan

@stocktitan.net

2 months ago

Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA Natera (NASDAQ:NTRA) announced a collaboration with NVIDIA to scale multimodal AI foundation models for precision medicine by integrating Natera’s longitudinal in vivo datasets and ML models with NVIDIA’s compute, libraries, and AI frameworks.Key elements: use of Parabricks, BioNeMo, and NeMo Agent Toolkit; NeoSelect and NeoPredict algorithms with claimed outperformance versus peers 2x improvement in immunotherapy response hazard ratios); early engineering gains of -75.7% run time, -59.2% cost, and +45.5% training speed.

#NTRA Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA

www.stocktitan.net/news/NTRA/natera-to-scal...

StockTitan

@stocktitan.net

2 months ago

Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera™ Growth Total revenues of approximately $660 million in the fourth quarter of 2025 compared to $476 million in the fourth quarter of 2024, an increase of approximately 39%. Total revenues, excluding revenue true-ups, were greater than $600 million. Total revenues of approximately $2.3 billion in the full year 2025 compared to $1.7 billion in the full year 2024, an...

#NTRA Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera™ Growth

www.stocktitan.net/news/NTRA/natera-announc...

StockTitan

@stocktitan.net

3 months ago

Natera Presents Updated Analyses From ALTAIR Clinical Trial at ASCO GI Natera (NASDAQ: NTRA) will present updated analyses from the phase III ALTAIR trial at ASCO GI (Jan 8–10, 2026). A post‑hoc blinded central radiographic review reclassified cases and showed a statistically significant disease‑free survival (DFS) benefit for Trifluridine/Tipiracil (FTD/TPI) versus placebo in Signatera‑positive colorectal cancer patients (median DFS 9.23 vs 5.55 months; HR 0.75, 95% CI: 0.55–0.98; P=0.0406). This result updates a prior overall ALTAIR analysis that was numerically improved but not statistically significant. Natera will also present data on Signatera velocity showing ~40% shorter RFS with ctDNA doubling ≤1 month.

#NTRA Natera Presents Updated Analyses From ALTAIR Clinical Trial at ASCO GI

www.stocktitan.net/news/NTRA/natera-present...

Bill Holobowski

@njhorseplayer.bsky.social

3 months ago

The happy recap on qualifying for the National Handicapping Championship (NHC26) in Las Vegas next March: www.njhorseplayer.com #NHC26 #NTRA #monmouthpark #thoroughbred #handicappingcontest

StockTitan

@stocktitan.net

3 months ago

Blood test helps spot colon cancer patients who gain from celecoxib Phase III trial of 940 stage III colorectal cancer patients finds Signatera-positive cases see ~40% lower recurrence and death risk with celecoxib plus chemo.

#NTRA Natera Announces Publication of Signatera™ Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer

www.stocktitan.net/news/NTRA/natera-announc...

StockTitan

@stocktitan.net

3 months ago

#NTRA I-SPY 2 Publication in Nature Communications Shows Signatera™ Can Predict Treatment Response and Recurrence Risk in Early-Stage Breast Cancer

www.stocktitan.net/news/NTRA/i-spy-2-public...

StockTitan

@stocktitan.net

3 months ago

Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer Natera (NASDAQ: NTRA) and MEDSIR announced the MiRaDoR phase II multicenter trial (NCT05708235) testing Signatera Genome‑guided interventions in early‑stage HR+/HER2‑ breast cancer.Up to 60 Signatera‑positive patients without radiologic recurrence will be sequentially assigned to four arms: standard endocrine therapy (90 days) then switch to Arm B giredestrant, Arm C giredestrant+abemaciclib, or Arm D giredestrant+inavolisib for PIK3CA‑mutant patients. Primary endpoint: proportion with ≥90% ctDNA decrease/clearance at 3 months. Enrollment is underway with UK sites active and further European activations expected in 2026.

#NTRA Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer

www.stocktitan.net/news/NTRA/natera-and-med...

StockTitan

@stocktitan.net

4 months ago

Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post‑Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2‑ Breast Cancer Natera, Inc., a global leader in cell-free DNA and precision medicine, together with Alliance Foundation Trials, LLC and the Austrian Breast and Colorectal Cancer Study Group, today announced initial translational research results from the international randomized Phase III PALLAS study. Presented today at the San Antonio Breast Cancer Symposium, these...

#NTRA Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post‑Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2‑ Breast Cancer

www.stocktitan.net/news/NTRA/phase-iii-pall...

StockTitan

@stocktitan.net

4 months ago

#NTRA Natera Highlights New Findings in Lymphoma at the ASH Annual Meeting

www.stocktitan.net/news/NTRA/natera-highlig...

Market Wire News

@marketwirenews.com

4 months ago

BREAKING NEWS: ( NASDAQ: #NTRA ) 30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks

StockTitan

@stocktitan.net

5 months ago

Natera Announces Expansion to 20 Genes for its Fetal Focus™ Single-Gene NIPT Natera (NASDAQ: NTRA) will expand its Fetal Focus single-gene NIPT from the initial 5-gene panel to a 20-gene panel, with the expanded test launching in Q4 2025. The assay uses Natera's LinkedSNP™ technology to detect challenging homozygous fetal mutations from maternal cfDNA.Anecdotally, Fetal Focus identified a pregnancy homozygous for the delta F508 cystic fibrosis mutation that another laboratory missed. Natera initiated the prospective EXPAND trial in 2023; EXPAND has enrolled approximately 1,700 patients with genetic confirmation of all outcomes and reported an initial readout where Fetal Focus identified 5 of 5 homozygous cases.

#NTRA Natera Announces Expansion to 20 Genes for its Fetal Focus™ Single-Gene NIPT

www.stocktitan.net/news/NTRA/natera-announc...

StockTitan

@stocktitan.net

5 months ago

Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity Natera (NASDAQ: NTRA) reported prospective PROCEED-CRC trial results for detection of advanced adenomas (AA) from ~1,400 cases collected before the cutoff date.The analysis included 92 sequential AA samples and 366 normal controls, showing AA sensitivity 22.5% (95% CI: 15.4%–32.4%) and specificity 91.5% (95% CI: 88.2%–93.9%). Adjusting for subtype prevalences from two recent FDA-enabling trials produced sensitivities of 22.4% and 23.7%. Most AA lesions were small: 98.9% 93.5% 95% sensitivity and 91% specificity. Findings support confidence ahead of the ongoing FIND FDA-grade validation trial initiated in 2025.

#NTRA Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity

www.stocktitan.net/news/NTRA/natera-reports...

Market Wire News

@marketwirenews.com

5 months ago

Just In: ( NASDAQ: #NTRA ) Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients

StockTitan

@stocktitan.net

5 months ago

Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients Natera, Inc., a global leader in cell-free DNA and precision medicine, today announced results from the randomized, double-blind, phase 3 IMvigor011 clinical trial in muscle-invasive bladder cancer. The findings demonstrate that Signatera can expand the adjuvant treatment window and guide the use of adjuvant atezolizumab in MIBC, resulting in improved...

#NTRA Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients

www.stocktitan.net/news/NTRA/successful-i-m...

Wire to Wire, Florida's Daily Thoroughbred Digest

@wiretowiredigest.bsky.social

7 months ago

What’s Racing Thorough Washington: A Federal Legislative Update from the NTRA - FTBOA [...]

‼️ What’s Racing Through Washington: A Federal Legislative Update from the #NTRA ‼️

#Wire2Wire #HorseRacing ⬇️

StockTitan

@stocktitan.net

7 months ago

Court Invalidates Patent Claims: Natera's Legal Battle with NeoGenomics Takes New Turn, Core Patent Stands Court invalidates claims in two Natera patents against NeoGenomics' RaDaR v1.1 test. Key '035 patent remains valid, maintaining injunction on RaDaR v1.0. Company holds 500+ patents globally.

#NTRA Natera Provides Update on Patent Litigation with NeoGenomics

www.stocktitan.net/news/NTRA/natera-provide...

StockTitan

@stocktitan.net

7 months ago

Signatera™ Test Selected for NRG-Sponsored Phase III ARCHER Trial in Bladder Cancer Natera (NASDAQ: NTRA) has announced the activation of the ARCHER (NRG-GU015) trial, a pivotal Phase III study in muscle-invasive bladder cancer (MIBC). The study will evaluate whether a shorter radiation course can match current standard-of-care outcomes, incorporating Natera's Signatera™ personalized molecular residual disease (MRD) test as a secondary endpoint.The trial, sponsored by NRG Oncology through the National Cancer Institute, will involve over 100 sites across the U.S. and Canada. Signatera will monitor circulating tumor DNA (ctDNA) clearance patterns to predict treatment response and recurrence, with additional exploration of urine tumor DNA. The test has been clinically validated to detect MIBC recurrence earlier than standard imaging. This initiative builds on Natera's existing MIBC clinical evidence, including positive results from the IMVigor011 trial, which demonstrated Signatera's effectiveness in predicting immunotherapy benefits post-cystectomy.

#NTRA Signatera™ Test Selected for NRG-Sponsored Phase III ARCHER Trial in Bladder Cancer

www.stocktitan.net/news/NTRA/signatera-tm-t...

StockTitan

@stocktitan.net

7 months ago

300+ Scientific Publications: How Natera's DNA Testing is Transforming Cancer, Pregnancy Care Global DNA testing leader Natera reaches 300+ peer-reviewed papers, including 150+ oncology, 100+ women's health, and 60+ organ health publications in top journals like Nature.

#NTRA Natera Technology Featured in 300+ Peer-Reviewed Publications, Underscoring Scientific Leadership in Precision Medicine

www.stocktitan.net/news/NTRA/natera-technol...

StockTitan

@stocktitan.net

7 months ago

Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation Natera (NASDAQ: NTRA) has launched its proprietary AI foundation model platform aimed at advancing diagnostic and therapeutic innovation in precision medicine. The platform is built on one of the largest multimodal oncology datasets, including over 250,000 tumor exomes and 1 million+ plasma timepoints.The platform consists of three integrated layers: a data foundation layer with extensive oncology datasets, a core model layer powered by over 1 billion parameters, and an application layer featuring tools like the Digital Patient Simulator, Real-Time Trial Matching, and NeoPredict. Initial pilot programs have demonstrated strong performance in recommending immunotherapy and predicting treatment responses.

#NTRA Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation

www.stocktitan.net/news/NTRA/natera-launche...

StockTitan

@stocktitan.net

7 months ago

98% 18-Month Survival Rate: Natera's Breakthrough Bladder Cancer Test Proves Critical for Immunotherapy Success Phase III IMvigor011 trial shows Signatera-positive patients benefit from atezolizumab treatment. Signatera-negative patients achieved 98% survival at 18 months without treatment. FDA submission planned.

#NTRA IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit

www.stocktitan.net/news/NTRA/i-mvigor011-bl...

StockTitan

@stocktitan.net

8 months ago

Natera Highlights Latest Prospera™ Data at WTC 2025; 16 Abstracts Including Five Oral Presentations Natera (NASDAQ: NTRA) announced its significant presence at the 2025 World Transplant Congress (WTC) with 16 abstracts, including five oral presentations, showcasing comprehensive data on its Prospera™ test across kidney, heart, and lung transplantation. The presentations highlight results from the Trifecta series of studies and include data from recently published studies in the American Journal of Transplantation, such as the PEDAL clinical trial for kidney transplants and Prospera Heart's performance with Donor Quantity Score (DQS).Key presentations feature Prospera Kidney's utility in monitoring treatment of chronic antibody-mediated rejection and various studies demonstrating the test's effectiveness across different transplant types. The congress, taking place August 2-6 in San Francisco, represents one of the most extensive collections of data on Natera's Prospera test to date.

#NTRA Natera Highlights Latest Prospera™ Data at WTC 2025; 16 Abstracts Including Five Oral Presentations

www.stocktitan.net/news/NTRA/natera-highlig...